Eli Lilly to Acquire Centessa in Deal Valued Up to $7.8 Billion
In Brief
The acquisition signals Eli Lilly's expansion into the sleep disorder drug market and its continued investment in new treatment areas.
Key Facts
- Eli Lilly has agreed to acquire Centessa for up to $7.8 billion.
- Centessa develops experimental drugs targeting sleep disorders, including narcolepsy.
- The deal is part of Lilly's broader strategy to expand beyond its GLP-1 franchise.
- Bloomberg Intelligence noted this marks Lilly's entry into the sleep disorder drug sector.
- Lilly has been an active dealmaker, supported by strong sales from its GLP-1 products.
What Happened
Eli Lilly announced an agreement to acquire Centessa, a company focused on experimental sleep disorder drugs, for up to $7.8 billion.
Why It Matters
This acquisition could diversify Lilly's portfolio and increase its presence in the treatment of sleep disorders, an area with ongoing research and unmet needs.
What's Next
Observers will watch for regulatory review of the deal and updates on the progress of Centessa's experimental narcolepsy treatments.
Sources
- MarketWatch — Lilly to pay up to $7.8 billion to buy a company developing a narcolepsy drug(1d ago)
- Bloomberg Markets — Why Eli Lilly Is Buying Centessa for $7.8 Billion(1d ago)
- CNBC — Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs (1d ago)